Medicus Pharma Ltd. Announces Change of Auditor
Medicus Pharma Ltd. has announced a change in its auditing firm, with MNP LLP resigning and EisnerAmper LLP being appointed as the new auditor. The transition, effective December 19, 2024, was ...
Medicus Pharma initiated at buy by Brookline Capital
Brookline Capital Markets initiated coverage of Medicus Pharma (MDCX) with a buy rating, citing the potential of its basal ...
Medicus Pharma Ltd: Innovative D-MNA Product Positions Company for Success with Favorable Buy Rating
Medicus Pharma Ltd (MDCX) has received a new Buy rating, initiated by Brookline Capital Markets analyst, Kumaraguru Raja.Don't Miss Our ...
Stockhouse on MSN9d
Medicus Pharma With Executive Chairman & CEO, Raza Bokhari, MD | December 19th, 2024
The Market Online speaks with Medicus Pharma Executive Chairman & CEO, Raza Bokhari, MD as Medicus Pharma Ltd. Announces ...
Hosted on MSN10d
ChartWatch ASX Scans: Pro Medicus, Perenti, Redox, Solvar, Telix Pharma, Westgold, Ampol, Clinuvel Pharma, Newmont, Ramsay Health, Sayona
Kogan.Com (KGN), Nick Scali (NCK), Orthocell (OCC), Pro Medicus (PME), Perenti (PRN), Qantas (QAN), Redox (RDX), Solvar (SVR) ...
The Times Leader10d
King’s College event raises $237,655 for financially at-risk students
Ciaruffoli serves on numerous for-profit and nonprofit boards, including Chair of the Audit Committee of Medicus Pharma Ltd., ...
malaymail16d
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
Toronto, Ontario and Philadelphia, Pennsylvania - Newsfile Corp. - December 12, 2024 - Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce that its ...
TMCnet16d
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
TORONTO and PHILADELPHIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce that its Investigational New Animal Drug ...
kalkinemedia16d
How Medicus Pharma Is Redefining SCC Treatment for Horses with D-MNA
Highlights:,Medicus Pharma Ltd.has received Minor Use in Major Species Designation (MUMS) from the FDA for its Doxorubicin-containing microneedle array (D-MNA) to treat equine squamous cell carcinoma.